Published in Arch Dermatol on August 01, 1974
The dermatophytes. Clin Microbiol Rev (1995) 4.59
Atopic dermatitis and fungi. Clin Microbiol Rev (2002) 1.29
Delayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformans. Infect Immun (1978) 0.97
Specificity of immunoglobulin E in coccidioidomycosis and correlation with disease involvement. Infect Immun (1982) 0.96
Cell-mediated immunity in experimental murine dermatophytosis. II. Adoptive transfer of immunity to dermatophyte infection by lymphoid cells from donors with acute or chronic infections. Immunology (1984) 0.96
Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev (1995) 0.91
Failure of treatment in chronic dermatophyte infections. Postgrad Med J (1979) 0.86
Cell-mediated immunity in experimental murine dermatophytosis. I. Temporal aspects of T-suppressor activity caused by Trichophyton quinckeanum. Immunology (1984) 0.85
Immunoglobulin E in histoplasmosis. Infect Immun (1980) 0.80
Genetic predictors of susceptibility to cutaneous fungal infections: a pilot genome wide association study to refine a candidate gene search. J Dermatol Sci (2012) 0.79
Reduced proliferative responses of peripheral blood mononuclear cells specifically to Candida albicans antigen in patients with atopic dermatitis--comparison with their normal reactivity to bacterial superantigens. Arch Dermatol Res (1996) 0.77
Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J (2016) 0.75
Application of immunological principles in dermatology. J Natl Med Assoc (1975) 0.75
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol (1992) 12.13
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Antifungal susceptibility testing. Clin Microbiol Rev (1993) 9.04
Resistance of Candida species to fluconazole. Antimicrob Agents Chemother (1995) 9.04
Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol (1988) 8.67
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol (2000) 6.33
Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol (1995) 6.02
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol (1994) 4.27
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Use of potato flakes agar in clinical mycology. J Clin Microbiol (1982) 3.73
Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J Clin Microbiol (1994) 3.62
Antifungal susceptibility testing. Current state of technology, limitations, and standardization. Infect Dis Clin North Am (1993) 3.55
Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1994) 3.46
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol (1986) 3.40
Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis (1997) 3.27
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis (1989) 3.14
Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother (1998) 3.00
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol (1999) 2.82
Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J Clin Microbiol (1994) 2.81
Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother (1988) 2.73
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol (1995) 2.66
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol (1998) 2.65
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61
Feature-linked synchronization of thalamic relay cell firing induced by feedback from the visual cortex. Nature (1994) 2.60
National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis (1998) 2.56
Mycoses caused by Candida lusitaniae. Rev Infect Dis (1988) 2.53
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates. J Clin Microbiol (1998) 2.48
Standardization of antifungal susceptibility testing. J Med Vet Mycol (1992) 2.43
Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol (1996) 2.28
In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother (1997) 2.27
Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol (2010) 2.19
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol (2005) 2.18
Invasive aspergillosis. Rev Infect Dis (1984) 2.18
Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J Clin Microbiol (1986) 2.17
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother (2000) 2.13
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother (1995) 2.12
Fluconazole-resistant Candida albicans. Clin Infect Dis (1993) 2.10
The metabolism of megestrol acetate (17-alpha-acetoxy-6-methylpregna-4, 6-diene-3, 20-dione) in the rabbit. Steroids (1965) 2.09
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis (1998) 2.03
Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol (2009) 2.02
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis (1996) 1.99
A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes (1982) 1.99
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother (1994) 1.95
Visual cortical mechanisms detecting focal orientation discontinuities. Nature (1995) 1.92
Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1991) 1.91
Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection. Antimicrob Agents Chemother (1989) 1.89
Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis (1994) 1.88
Intra-articular steroids in osteoarthritis. Rheumatol Rehabil (1980) 1.85
The influence of medium composition on the growth and swarming of Proteus. J Gen Microbiol (1967) 1.84
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother (1993) 1.83
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother (1995) 1.77
Left-Handedness in Twins. Genetics (1932) 1.73
Evaluation of the E test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. J Antimicrob Chemother (1995) 1.72
Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol (1998) 1.72
Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 1.72
Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol (1999) 1.71
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother (2000) 1.68
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis (1998) 1.66
In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1999) 1.62
Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol (1996) 1.61
Oral, subcutaneous and intratracheal administration of carcinogenic lactones and related substances: the intratracheal administration of cigarette tar in the rat. Br J Cancer (1966) 1.60
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med (2000) 1.58
Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol (2007) 1.58
Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol (1990) 1.57
Ocular penetration and pharmacokinetics of topical fluconazole. Cornea (1997) 1.56
Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol (1998) 1.55
Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant (2006) 1.55
Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol (2007) 1.55
Scedosporium inflatum, an emerging pathogen. J Clin Microbiol (1988) 1.54
The short forms and long forms of Proteus. J Gen Microbiol (1967) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother (2000) 1.48
The laryngeal mask airway in paediatric anaesthesia. Anaesthesia (1990) 1.47
Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes. Drug Alcohol Depend (2001) 1.46
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis (1994) 1.46
Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun (2005) 1.44
Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol (1999) 1.44
Spectrum of clinically relevant Exophiala species in the United States. J Clin Microbiol (2007) 1.44
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1999) 1.43
In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother (2001) 1.42
Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1995) 1.42
Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother (1996) 1.41
Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol (2002) 1.40
Oestrogens in the blood of the cow. J Endocrinol (1965) 1.39